five

Phase I trial of Cetuximab combined with S-1 and irrinotecan in advanced colorectal cancer

收藏
NIAID Data Ecosystem2026-03-06 收录
下载链接:
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2619160
下载链接
链接失效反馈
官方服务:
资源简介:
Interventions: Cetuximab: Weekly administration 400 mg/m2 for the 1st time (day1), 250mg/m2/week for the 2nd time or another (day8,15,..) TS-1 is orally administered b.i.d. on days 1-14 and CPT-11 is intravenously administered on days 1 every 3 weeks S-1:Level1 65mg/m2 day1-14 Level2 80mg/m2 day1-14 CPT-11:Level1,2 150mg/m2, day1 Primary outcome(s): Maximum tolerated dose Recommended dose Study Design: Single arm Non-randomized
创建时间:
2010-06-15
二维码
社区交流群
二维码
科研交流群
商业服务